Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04674748 | To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | terminated | Phase 1 | 3 | Incyte Biosciences Japan GKINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT03446040 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | terminated | Phase 1 / Phase 2 | 92 | Bristol-Myers SquibbINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT05077384 | Open-label Study of Surufatinib in Japanese Patients | completed | Phase 1 / Phase 2 | 36 | HutchmedINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04045795 | Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | completed | Phase 1 | 56 | SanofiINDUSTRY | 6 | Sep 12, 2025 | clinicaltrials |
| NCT04702737 | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer(DeLLpro-300) | completed | Phase 1 | 41 | AmgenINDUSTRY | 9 | Sep 12, 2025 | clinicaltrials |
| NCT03836053 | Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma(AMG420) | terminated | Phase 1 | 23 | AmgenINDUSTRY | 5 | Sep 11, 2025 | clinicaltrials |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | PfizerINDUSTRY | 3 | Sep 5, 2025 | clinicaltrials |
| NCT02310321 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | completed | Phase 1 / Phase 2 | 97 | Astellas Pharma IncINDUSTRY | 3 | Sep 2, 2025 | clinicaltrials |
| NCT06074705 | A Study of DS-1471a In Subjects With Advanced Solid Tumors | terminated | Phase 1 | 17 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT03828292 | An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | completed | Phase 1 | 15 | GlaxoSmithKlineINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT02099058 | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 237 | AbbVieINDUSTRY | 9 | Aug 14, 2025 | clinicaltrials |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | terminated | Phase 1 | 139 | Novartis PharmaceuticalsINDUSTRY | 10 | Aug 11, 2025 | clinicaltrials |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | active not recruiting | Phase 1 | 8 | AbbVieINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05685472 | MEDI5752 in Japanese Patients With Advanced Solid Tumors. | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02836600 | A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04541433 | A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer | completed | Phase 1 | 10 | AstraZenecaINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03324113 | Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT06853496 | Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer | recruiting | Phase 1 | 48 | Eiji ShinozakiOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | completed | Phase 1 | 171 | AmgenINDUSTRY | 13 | Jul 20, 2025 | clinicaltrials |
| NCT04153565 | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04454658 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 14 | Jul 16, 2025 | clinicaltrials |
| NCT04937153 | GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | completed | Phase 1 | 18 | GenmabINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT03816839 | Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)(AMEERA-2) | terminated | Phase 1 | 10 | SanofiINDUSTRY | 1 | Jul 7, 2025 | clinicaltrials |
| NCT06548217 | A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 31 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants(CML) | recruiting | Phase 1 | 21 | Enliven TherapeuticsINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 226 | Janssen Research & Development, LLCINDUSTRY | 12 | Jun 22, 2025 | clinicaltrials |
| NCT04676477 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 246 | Daiichi SankyoINDUSTRY | 4 | Jun 22, 2025 | clinicaltrials |
| NCT02145741 | Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07016997 | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06535009 | Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors | terminated | Phase 1 | 25 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06541665 | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | active not recruiting | Phase 1 | 20 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 | 37 | National Cancer Center, JapanOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT04405778 | A Study of TAK-102 in Adult With Previously-Treated Solid Tumors | terminated | Phase 1 | 12 | TakedaINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT05192174 | Study of NIB101 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 3 | Noile-Immune Biotech, IncINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | terminated | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | May 18, 2025 | clinicaltrials |
| NCT04261439 | A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | terminated | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 7 | May 6, 2025 | clinicaltrials |
| NCT05863234 | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia | recruiting | Phase 1 / Phase 2 | 7 | Hiroshima University HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03260322 | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 169 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Apr 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials